ProMIS Neurosciences details new ALS and Parkinson’s data
ProMIS Neurosciences showcased significant advancements in neurodegenerative disease research at the Alzheimer’s & Parkinson’s Diseases (AD/PD) 2026 conference in Copenhagen. On March 20, Neil Cashman presented a rationally designed vaccine targeting a pathogenic TDP-43 epitope, while Johanne Kaplan reported on the elicitation of an antibody response against toxic alpha-synuclein species through vaccination with computationally modeled conformational epitopes.
These presentations underscore ProMIS’s commitment to its proprietary EpiSelect discovery platform, which aims to selectively target toxic misfolded proteins associated with neurodegenerative conditions. The company highlighted its lead Alzheimer’s candidate, PMN310, which received U.S. FDA Fast Track designation in July 2025 and is currently undergoing the PRECISE-AD Phase 1b study to assess safety and tolerability in patients with mild cognitive impairment and mild Alzheimer’s disease.
The implications of this research are substantial, as it may pave the way for innovative therapeutic strategies that specifically target the underlying pathologies of neurodegenerative diseases.